Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.47 |
| ▸ | PDE4A | P27815 | 7/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165899 | 0.93 | PDE4A (0.50) | TP53PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL1382807 | 0.93 | TP53 (0.49) | TP53PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL5513420 | 0.93 | PDE4A (0.50) | TP53PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL5519148 | 0.92 | TP53 (0.48) | TP53PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL14446879 | 0.90 | PDE4B (0.48) | TP53PDE4BPDE4CPDE4APDE4D | |
| Cyclopropane SCHEMBL15252730 | 0.90 | TP53 (0.49) | TP53PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL1384576 | 0.90 | TP53 (0.51) | TP53PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL13165898 | 0.90 | TP53 (0.51) | TP53PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL5516142 | 0.90 | TP53 (0.46) | TP53PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL13909302 | 0.90 | PDE4A (0.47) | TP53PDE4BPDE4CPDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4713465-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1605896-B1 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7799819-B2 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799819-B2 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090131505-A1 | 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses | MAN HON-WAH | 2009-05-21 | — | — | US | disclosed |
| US-20090131505-A1 | 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses | MAN HON-WAH | 2009-05-21 | — | — | US | disclosed |
| US-7511072-B2 | 7-amido-isoindolyl compounds and methods of its use | CELGENE CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511072-B2 | 7-amido-isoindolyl compounds and methods of its use | CELGENE CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070254942-A1 | 7-amido-isoindolyl compounds and methods of its use | CELGENE CORPORATION. | 2007-11-01 | — | — | US | disclosed |
| US-20070254942-A1 | 7-amido-isoindolyl compounds and methods of its use | CELGENE CORPORATION. | 2007-11-01 | — | — | US | disclosed |
| US-7256210-B2 | 7-amido-isoindolyl compounds and methods of their use | CELGENE CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256210-B2 | 7-amido-isoindolyl compounds and methods of their use | CELGENE CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256210-B2 | 7-amido-isoindolyl compounds and methods of their use | CELGENE CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060058362-A1 | 7-Amido-isoindolyl compounds and methods of their use | MAN HON-WAH | 2006-03-16 | — | — | US | disclosed |
| WO-2004080423-A2 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058362-A1 | 7-Amido-isoindolyl compounds and methods of their use | MCL1, APC, HPGDS | TP53 262/4885PDE4B 2106/4885PDE4C 1281/4885 |
| US-20090131505-A1 | 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses | THPO, MCL1, HPGDS | TP53 276/4885PDE4B 564/4885PDE4C 874/4885 |
| US-20070254942-A1 | 7-amido-isoindolyl compounds and methods of its use | MCL1, THPO, APC | TP53 192/4885PDE4B 1964/4885PDE4C 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.